Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells
Author(s) -
Lorenz C. Hofbauer,
K. C. Hicok,
D Chen,
Sundeep Khosla
Publication year - 2002
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje.0.1470269
Subject(s) - medicine , endocrinology , osteoprotegerin , androgen receptor , dihydrotestosterone , bone resorption , androgen , chemistry , osteoblast , stromal cell , downregulation and upregulation , rankl , osteoclast , estrogen receptor , receptor , biology , activator (genetics) , in vitro , hormone , biochemistry , prostate cancer , cancer , breast cancer , gene
Estrogens and androgens have anti-resorptive effects on bone, although recent evidence indicates that, even in men, estrogen is the dominant sex steroid regulating bone resorption. The receptor activator of NF-kappaB ligand is essential for osteoclastic bone resorption, and its effects are blocked by the decoy receptor, osteoprotegerin (OPG). While estrogen has been shown to induce osteoblastic OPG production, the effects of androgens on OPG production have not been defined.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom